ESRRB and breast carcinoma: In addition, trastuzumab (and subsequent biosimilar drugs) have been licenced for use not just for patients with ERRB2 positive breast cancer, but also gastric cancer [4]; and its derivatives show promise in other cancers such as ERRB2 positive non-small-cell lung cancer [5] and are being tested in others [6].